Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153420 | 0.84 | ALDH1A1 (0.36) | ALDH1A1POLBKMT2ATLR8CYP19A1 | |
| SCHEMBL18038297 | 0.77 | KMT2A (0.42) | ALDH1A1POLBKMT2ATLR8CYP19A1 | |
| SCHEMBL13099877 | 0.73 | TLR8 (0.58) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL201430 | 0.73 | KMT2A (0.43) | ALDH1A1POLBKMT2ATLR8CYP19A1 | |
| SCHEMBL6767037 | 0.73 | ALDH1A1 (0.45) | ALDH1A1POLBKMT2ATLR8CYP1A2 | |
| SCHEMBL2513945 | 0.71 | KMT2A (0.53) | ALDH1A1POLBKMT2ACYP19A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3304863 | 0.69 | ALDH1A1 (0.35) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL28470170 | 0.69 | KCNH2 (0.36) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL2061624 | 0.69 | ALDH1A1 (0.35) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL14451168 | 0.68 | SMN1; SMN2 (0.38) | ALDH1A1POLBKMT2ATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130343988-A1 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer | EXELIXIS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100209340-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6982268-B2 | Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-01-03 | — | — | US | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1501825-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041809-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES AND THEIR USE AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1406906-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1368342-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2003006471-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002050062-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | ALDH1A1 470/4885POLB 3712/4885KMT2A 1769/4885 |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | ALDH1A1 797/4885POLB 4332/4885KMT2A 1549/4885 |
| US-20130343988-A1 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer | CDKN1A, MAP3K3, CCNK | ALDH1A1 2269/4885POLB 635/4885KMT2A 1657/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | ALDH1A1 470/4885POLB 3712/4885KMT2A 1769/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | ALDH1A1 470/4885POLB 3712/4885KMT2A 1769/4885 |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | GABRP, GABBR1, GABRA1 | ALDH1A1 512/4885POLB 4689/4885KMT2A 2464/4885 |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | ALDH1A1 553/4885POLB 4266/4885KMT2A 1159/4885 |
| US-20100209340-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | CDKN1A, CCNK, MAP3K3 | ALDH1A1 2209/4885POLB 535/4885KMT2A 1413/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | ALDH1A1 220/4885POLB 3711/4885KMT2A 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.